Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Inclusion Criteria:

• The participant must have been diagnosed with RMS according to the 2017 revision ofthe McDonald diagnostic criteria.

• The participant has an EDSS score ≤5.5 at the first visit (Screening Visit)

• The participant must have at least 1 of the following prior to screening:

• ≥1 documented relapse within the previous year OR

• ≥2 documented relapses within the previous 2 years, OR

• ≥1 documented Gd enhancing lesion on an MRI scan within the previous year.

• Contraceptive use by men or women should be consistent with local regulationsregarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

• The participant has been diagnosed with PPMS according to the 2017 revision of theMcDonald diagnostic criteria

• The participant has a history of infection or may be at risk for infection:

• The presence of psychiatric disturbance or substance abuse.

• History, clinical evidence, suspicion or significant risk for thromboembolic events,as well as myocardial infarction, stroke, and/or antiphosholipid syndrome and anyparticipants requiring antithrombotic treatment.

• History or current hypogammaglobulinemia defined by values below the lower limit ofnormal (LLN).

• A history or presence of disease that can mimic MS symptoms, such as, but notlimited to neuromyelitis optica spectrum disorder, systemic lupus erythematosus,Sjogren's syndrome, acute disseminated encephalomyelitis, and myasthenia gravis.

• The participant has had a relapse in the 30 days prior to randomization.

• The participant has contraindication for MRI, ie, presence of pacemaker, metallicimplants in high risk areas (ie, artificial heart valves, aneurysm/vessel clips),presence of metallic material (eg, shrapnel) in high risk areas, known history ofallergy to any contrast medium, or history of claustrophobia that would preventcompletion of all protocol scheduled MRI scans.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.